Reneo Pharmaceuticals Analyst Ratings
Reneo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/14/2023 | 365.84% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 10/12/2023 | 365.84% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 09/08/2023 | 365.84% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/28/2023 | 365.84% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 07/03/2023 | 257.14% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 09/19/2022 | 381.37% | HC Wainwright & Co. | → $31 | Assumes | → Buy |
| 05/18/2022 | 179.5% | Piper Sandler | $45 → $18 | Maintains | Overweight |
| 03/24/2022 | 132.92% | SVB Leerink | $25 → $15 | Maintains | Outperform |
| 01/27/2022 | 334.78% | Baird | → $28 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 334.78% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/22/2021 | 598.76% | Ladenburg Thalmann | → $45 | Initiates Coverage On | → Buy |
| 05/04/2021 | 288.2% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 05/04/2021 | 272.67% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 05/04/2021 | 598.76% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | — | 威廉布萊爾 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 11/14/2023 | 365.84% | HC Wainwright & Co. | → 30 美元 | 重申 | 購買 → 購買 |
| 2023 年 12 月 10 日 | 365.84% | HC Wainwright & Co. | → 30 美元 | 重申 | 購買 → 購買 |
| 09/08/2023 | 365.84% | HC Wainwright & Co. | → 30 美元 | 重申 | 購買 → 購買 |
| 08/28/2023 | 365.84% | HC Wainwright & Co. | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/03/2023 | 257.14% | B of A 類證券 | → 23 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/19/2022 | 381.37% | HC Wainwright & Co. | → 31 美元 | 假設 | → 購買 |
| 05/18/2022 | 179.5% | 派珀·桑德勒 | 45 美元 → 18 美元 | 維護 | 超重 |
| 2022 年 3 月 24 日 | 132.92% | SVB Leerink | 25 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 01/27/2022 | 334.78% | 貝爾德 | → 28 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 12/21/2021 | 334.78% | HC Wainwright & Co. | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/22/2021 | 598.76% | 拉登堡塔爾曼 | → 45 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 4 月 5 日 | 288.2% | SVB Leerink | → 25 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 4 月 5 日 | 272.67% | 傑富瑞集團 | → 24 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 4 月 5 日 | 598.76% | 派珀·桑德勒 | → 45 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Reneo Pharmaceuticals (RPHM)?
瑞諾製藥（RPHM）的目標價格是多少？
The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by William Blair on November 15, 2023. The analyst firm set a price target for $0.00 expecting RPHM to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
威廉·布萊爾於2023年11月15日公佈了瑞諾製藥（納斯達克股票代碼：RPHM）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計RPHM將在12個月內降至-100.00％（可能下跌-100.00％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?
瑞諾製藥（RPHM）的最新分析師評級是多少？
The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by William Blair, and Reneo Pharmaceuticals initiated their outperform rating.
威廉·布萊爾對瑞諾製藥（納斯達克股票代碼：RPHM）的最新分析師評級由威廉·布萊爾提供，雷諾製藥啓動了跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?
瑞諾製藥（RPHM）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Reneo Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Reneo Pharmicals的最新評級是在2023年11月15日公佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?
分析師對瑞諾製藥（RPHM）的評級是否正確？
While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a initiated with a price target of $0.00 to $0.00. The current price Reneo Pharmaceuticals (RPHM) is trading at is $6.44, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Reneo Pharmicals（RPHM）評級是啓動的，目標股價爲0.00美元至0.00美元。Reneo Pharmicals（RPHM）目前的交易價格爲6.44美元，超出了分析師的預期區間。